Tendon, muscle crush and why BPC-157 is not TB-500

A tendon is dense, aligned type I collagen — sparsely cellular, poorly vascular, slow to turn over, and mechanically addicted to the load that also injures it. When it fails, the repair bed has to grow small vessels and lay collagen in the line of force rather than as a scar. Two named sequences sit near that injury in the animal papers, and they don't do the same job. Body protection compound-157 is a fifteen-residue fragment of a gastric-juice protein, proline-rich, stubborn in acid, and studied for three decades from a Zagreb laboratory as a cytoprotective and angiogenic probe. TB-500 is a laboratory analogue built around the LKKTETQ actin-binding motif of thymosin β4, the principal G-actin sequestering peptide of animal cells. Forum culture glued them into a healing stack because both showed up in injury models. Biochemistry didn't glue them. One talks, on the cleaner papers, to a receptor tyrosine kinase and to focal-adhesion kinase. The other parks actin monomers so a cell can push a lamellipodium.

In short. Two named peptides sit behind tendon searches. One talks to vessel and tendon cells. The other holds spare actin so a cell can crawl. They aren't the same job.

Muscle crush is the other search that lands on the same pair, and it's a different insult. A mechanical compression kills myofibres, opens capillaries, leaves a haematoma, and recruits satellite cells that either rebuild aligned fibres or lose the race to fibrosis. The Zagreb BPC-157 corpus ran crush models as a staple: function, fibre organisation, a vascular component again. Thymosin-β4 papers sit nearer to cell migration and to extracellular cues that make a leading edge. Those two injuries rhyme at the level of a person who can't train. They don't rhyme at the level of a histology slide. Tenocytes live in a dense collagen hierarchy and see load as their growth factor. Myofibres are multinucleate contractile cables with a stem-cell niche under the basal lamina. Bundling the tissues because both hurt after sport is how a forum talks. Unbundling them is the job of this page. The sequences are real chemistry. The injuries are real clinic objects. They don't become one object because a search bar put them on the same afternoon.

In short. Crushed muscle isn't a failed tendon. Different cells, different blood-supply problems, different clocks. The same two peptides keep turning up. That's a search habit, not a shared mechanism.

Sequence is identity, and identity is the first experiment. BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written GEPPPGKPADDAGLV, mass 1419.5 daltons, CAS 137525-51-0. Thymosin β4 is a forty-three-residue, intrinsically disordered peptide whose actin-binding motif is Leu-Lys-Lys-Thr-Glu-Thr-Gln. Research TB-500, as the trade analogue is usually sold, orbits that motif; full-length Tβ4 is a different object, and the N-terminal tetrapeptide Ac-SDKP is a third. HPLC-MS is how you know which of those you reconstituted. A forum abbreviation is how you pretend you already know. The rest of this piece is tendon anatomy, why that tissue is slow, what a crush actually destroys, what the named sequences did in the papers you can cite, and why a blot that can't tell VEGFR2 from a G-actin buffer shouldn't be asked to referee a stack. Soft-tissue medicine has its own evidence ladder: loading programmes, imaging, surgery when the cable is gone. These are the peptides those preclinical papers named. Mapping isn't treating.

In short. A peptide is its amino-acid sequence and its mass. BPC-157 is fifteen residues from a stomach protein. TB-500 orbits seven actin-binding letters. The certificate, not a forum name, says which one you have.

What follows isn't physiotherapy, not a reason to skip ultrasound or magnetic resonance imaging, and not a protocol for a rotator cuff. Tendinopathy is a clinic word with a continuum model, a loading literature, and a surgical drawer when the tendon has actually torn. Muscle crush in a person is an emergency when compartment pressure rises, and a rehabilitation problem when it doesn't. The animal papers that put a gastric 15-mer or an actin analogue into those neighbourhoods are real, cited, and mostly rodent. Independent groups have reproduced endothelial migration and some tenocyte-outgrowth findings more cleanly than the more extravagant extensions of either corpus. That reading is already set out in the BPC-157 and TB-500 essays on this desk. This page is the tissue page: the cable, the crush, the reason hypovascular collagen notices a vessel peptide, the reason a crawling cell notices an actin buffer, and the reason those two observations are still two observations. A characterised lyophilised sequence is a reagent. A clinic is where licensed care for tendon and muscle lives, and it will still live there when this page is closed.

In short. This is anatomy, injury biology and a paper trail. It isn't a loading programme, a scan, or a treatment plan for a person.

Type I collagen is the rope. In tendon it's packed as a hierarchy that textbooks still draw as a Russian doll: tropocollagen triple helices, microfibrils, fibrils with a 67-nanometre D-period you can see on electron microscopy, fibres, fibre bundles, fascicles wrapped in endotenon, the whole cable wrapped in epitenon, and, in many tendons, a synovial-like paratenon rather than a true sheath. Water and small proteoglycans — decorin, biglycan, fibromodulin — sit between the fibrils and tune sliding. Elastin is a minority component except at the myotendinous junction and the enthesis, where recoil and stress concentration both matter. The job is tensile: to take force from a muscle and hand it to a bone without stretching enough to waste the contraction and without snapping. Benjamin, Ralph, and a generation of connective-tissue anatomists spent careers on that hierarchy because once you have seen it, 'soft tissue' becomes an unusable phrase. A tendon isn't soft in the way a bruise is soft. It's a fibre-composite, anisotropic, and slow.

In short. A tendon is layered type I collagen, from triple helices up to fascicles, built to carry force from muscle to bone. It's a cable, not a bruise.

Tenocytes are the residents, and there aren't many of them. They sit in rows between collagen bundles, connected by gap junctions, and they look after a matrix they didn't so much secrete yesterday as maintain over months. Scleraxis is the transcription-factor marker the developmental papers use; tenomodulin is a glycoprotein marker of the mature lineage; mohawk is another. In culture they lose phenotype with passage, which is why a paper that says tendon fibroblast at passage twelve has already left the tissue. Their growth factor is load. Stretch, through integrins and the focal-adhesion machinery, writes collagen I, collagen III in a repair burst, and the cross-linking enzymes that make a fibril a fibril. Unload them and the matrix sags. Overload them, especially with compression or with a sudden spike after a layoff, and the tenocyte transcriptome shifts toward a failed-repair state that Cook and Purdam described as a continuum rather than an inflammation cartoon. Degenerative tendinopathy isn't redness as a synonym for injury. It's disordered collagen, a proteoglycan swamp, vessels and nerves that have sprouted into a tissue that used to be almost avascular, and pain that doesn't track a neat histological grade.

In short. Tendon cells are sparse, load-sensing caretakers of collagen. Degenerative tendon is disordered matrix and unwanted vessels and nerves, not a simple bruise.

The blood supply is the sentence that makes a gastric angiogenic peptide look, to a forum, like a tendon peptide. Many tendons have watershed zones where perfusion is already mean: the mid-portion Achilles a few centimetres above the calcaneus, the supraspinatus near its insertion, the tibialis posterior behind the medial malleolus. Vessels travel in the endotenon and paratenon. The fascicle interior is nourished as much by diffusion and by load-driven fluid flow as by a capillary at every door. That's why a tendon heals slowly, and why a repair bed that can't recruit small vessels will lay a scar that can't take load. It's also why the wrong vessels in the wrong place — the neovascularisation a Doppler ultrasound sees in a painful Achilles — aren't automatically a victory. Healthy adult tendon is hypovascular on purpose. Angiogenesis in a defect can be repair. Angiogenesis in a degenerative mid-portion can be part of the pain. A peptide literature that reports a denser bed of small vessels has reported a measurement. It hasn't yet told you which political verdict that measurement is serving.

In short. Tendons are poorly supplied with blood, especially in named watershed zones. New vessels can be repair in a defect or part of the pain in a degenerate cable.

The enthesis is where tendon becomes bone, and it's a different organ from the mid-portion. Four zones in the fibrocartilaginous version: dense fibrous tendon, uncalcified fibrocartilage, a tidemark, calcified fibrocartilage, then bone. Collagen II and aggrecan appear. The stress concentration is ugly; the biology is a gradient, not a glue. Tendon-to-bone is the repair problem a rotator-cuff surgeon actually has, and it's the model Chang, Tsai, Lin, Hsu and Pang, and the Zagreb group, put BPC-157 into: outgrowth, cell survival, migration, load-to-failure weeks later, collagen organisation, a vascular density in the repair bed. Mid-portion tendinopathy is a different clinical object — the painful Achilles of a mid-life runner, the patellar tendon of a jumper — and it isn't a hole you can suture. Enthesopathy, insertional Achilles, plantar fascia, the common extensor origin at the elbow: those sit on the gradient. A paper that says tendon and doesn't say mid-portion, insertion, or tendon-to-bone hasn't yet named the tissue. The 15-mer didn't become a different molecule when the model moved from stomach to insertion. The tissue did.

In short. Where tendon meets bone is a four-zone gradient, not a glue. Many BPC-157 papers use that junction. A painful mid-portion tendon is a different clinical object.

Ligament is the neighbouring cable, and the internet files it under the same search. Ligament connects bone to bone, sees a different loading pattern, and is often even less vascular than tendon. Collagen I still dominates; the fibril organisation is less strictly uniaxial; proprioceptive innervation is a larger part of the job. Anterior cruciate, medial collateral, ankle syndesmosis: those are ligaments. A hamstring strain is muscle. An Achilles tendinopathy is tendon. A rotator-cuff tear can be tendon, enthesis, and bursa at once. The peptide papers don't always keep those nouns honest. We will. Muscle crush, coming in a later heading, is myofibre necrosis plus a haematoma plus a satellite-cell decision, which is already three objects. A catalogue that stocks two sequences because searchers type one complaint is being generous about a reading list. It isn't being told by biochemistry that ligament, tendon and muscle are one ligand away from being the same tissue. They aren't.

In short. Ligament, tendon and muscle are three tissues. The search bar files them together. Anatomy does not, and neither does a blot.

Collagen turnover in adult tendon is slow enough that a chemist notices. Heinemeier, Schjerling, Kjaer and colleagues used atmospheric bomb-pulse carbon-14 to show that core Achilles collagen is largely laid down in adolescence and then kept, with a very low adult replacement rate in the dense interior. The periphery and the injury bed turn over faster. That's why a six-week rodent load-to-failure paper and a two-year human tendinopathy aren't the same clock. Cross-links — lysyl oxidase products, and the advanced glycation products that accumulate with age and with diabetes — stiffen the cable and make it less forgiving. Collagen III appears in repair and in degenerate tendon; it's thinner, more extensible, a scaffold that's supposed to be replaced by aligned type I. A hydroxyproline assay that can't tell I from III has measured 'more collagen' and hasn't measured a tendon. Polarised-light birefringence, picrosirius red, a second-harmonic image, a scleraxis stain, a load-deformation curve: those are how a paper asks whether the new matrix is a cable or a scar.

In short. The dense core of an adult tendon replaces its collagen very slowly. More collagen on a chemical test isn't the same as a cable lined up to take load.

Load is the growth factor, which is why the clinic's best-replicated tool is a loading programme and not a vial. Alfredson's eccentric Achilles protocol, later isometric and heavy-slow-resistance variants from Kongsgaard, Rio, and others, move pain and function in tendinopathy cohorts with an effect size a peptide paper would envy. The mechanism, as far as a tissue can be said to have one, is tenocytes being asked to write aligned collagen under a dose of strain they can actually complete. Complete is the word. A programme that the person can't load through, because pain or because life, doesn't get to write the matrix. Rest as a sole intervention is how a cable destensions and a runner loses six months. Surgery has a place when the cable is torn, when a Haglund deformity is a mechanical insult, when a rotator cuff has retracted past a reconstructable geometry. Platelet-rich plasma, extracorporeal shockwave, sclerosant injection of neovessels: mixed trials, some signals, not a closed physiology. Soft-tissue medicine already has an evidence ladder. A research 15-mer and an actin analogue don't inherit a rung by proximity.

In short. The best-replicated tendon treatment is a loading programme that asks tendon cells to write aligned collagen. Rest, injections and surgery have their places. These peptides don't replace that ladder.

The clinic nouns are worth keeping separate because the papers blur them. Tendinopathy is the painful, load-related, often degenerative cable; the old word tendinitis oversold inflammation. A tear is a discontinuity, partial or full-thickness, which imaging can see and a surgeon can sometimes fix. Enthesopathy is the insertion. Paratenonitis is the sleeve. A muscle strain is a myofibre and myotendinous-junction injury graded by how much of the cable still works. Crush is compression, often with a haematoma, sometimes with a compartment syndrome that's a surgical emergency and not a peptide question. Imaging — ultrasound first for many tendons, magnetic resonance when the question is tear, retraction, or a muscle belly — is how a clinic names the object. Skipping the image because a forum named a stack is how a person spends a year treating the wrong tissue. This page will keep saying so without turning into a guideline. The peptides below sit on named animal models of some of those objects. The models aren't the clinic nouns. The clinic nouns aren't a receptor.

In short. Painful degenerate tendon, a tear, an insertion problem and a crushed muscle are different diagnoses. A scan names the object. A forum stack does not.

Crush is a dirty model, which is both its virtue and its vice. A clamp or drop-weight kills myofibres, tears capillaries, leaves a haematoma, and sets a clock in which neutrophils arrive first, macrophages second, and satellite cells third. The satellite cell, sitting under the basal lamina, is the muscle stem cell: Pax7-positive, able to activate, proliferate, and fuse to rebuild a fibre, or to stall and leave a fibrotic gap. Charge and Rudnicki, Grounds, and a regeneration literature that's older than either peptide, mapped that niche. Reperfusion after the compression is a second injury: calcium, reactive oxygen, a burst the antioxidant-enzyme people already know. Fibrosis is the failure mode if the inflammatory wave doesn't resolve and if fibroblasts win the matrix. A crushed quadriceps in a rat looks, to a person, like an injury they recognise. It also confounds everything at once: vessels, nerves, myofibres, haematoma, pain, load. That's why a clean myoblast-migration assay in a dish, with a characterised peptide and a named inhibitor on the next well, is the experiment that would make a muscle claim mechanistic. Some of that work exists. Not enough exists outside the laboratories that already believed the peptide.

In short. Crushing a muscle kills fibres, opens vessels and asks stem cells to rebuild before scar wins. A clean cell-migration test matters more than a photograph of a rat.

The Zagreb BPC-157 muscle papers report faster restoration of function, better fibre organisation, and again a vascular component. Novinscak, Seiwerth, Sikiric and colleagues put the 15-mer into crush and transection models and photographed the result. The pattern is now familiar from the gastric and tendon files: a large in-vivo phenotype, repeated in-house, with a molecular paper that would make a biochemist relax arriving thinner and later. A crushed muscle that recovers faster might have done so because vessels came back, because satellite cells fused, because fibrosis was quieter, because the animal used the limb, or because the scoring was hopeful. Those are different mechanisms. VEGFR2 and FAK, the nodes independent endothelial and tenocyte papers actually named, can be invoked here as a hypothesis: a repair bed needs perfusion, and a myoblast needs to crawl. Invoking them isn't showing them. Showing them is a phospho-blot, an inhibitor, a satellite-cell count, a Picrosirius scar fraction, and a second laboratory. Until that panel exists, crush is a phenotype in a single-lab programme, and a phenotype is allowed, but it isn't yet a muscle mechanism.

In short. The original BPC-157 muscle papers report faster recovery in rats. That's a phenotype from one programme. A mechanism would name vessels, stem cells or scar with inhibitors and a second lab.

Thymosin β4 sits nearer to the crawl than to the crush, which is already a clue that the two peptides aren't a matched pair for this insult. Malinda, Goldstein and Kleinman showed endothelial migration toward Tβ4 in 1997. Sosne’s cornea is an epithelium that must crawl. Bock-Marquette’s heart paper named integrin-linked kinase and a survival-and-migration phenotype in a coronary-ligation model, full-length 43-mer, Nature 2004. A motif analogue in a lyophilised cake isn't automatically that ligand. Muscle regeneration does use actin: a myoblast that can't make a lamellipodium won't find a fibre to fuse with. That sentence makes an actin-buffer peptide a lawful probe in a migration assay. It doesn't make TB-500 a crush medicine, and it doesn't make it a second BPC-157. Myofibres and tenocytes don't share a stem-cell niche, a collagen hierarchy, or a vascular pattern. They share, at most, a person who wants to train on Tuesday. The insult that destroyed the tissue still has to be named. Crush isn't tendinopathy. Tendon-to-bone isn't a haematoma. The peptides didn't collapse those sentences. The search bar did.

In short. The actin peptide’s cleaner papers are about cells crawling, not about a clamp on a muscle. Crawl biology is real. It's still not the same insult as a failed tendon or a crush.

Body protection compound was the name Predrag Sikiric’s group in Zagreb gave to a proteinaceous activity in human gastric juice that cytoprotected mucosa against a catalogue of insults. BPC-157 is the synthetic pentadecapeptide they took from that work and put into print, from the early 1990s, as a stable fragment that still did the job. Write the residues: GEPPPGKPADDAGLV. Four prolines in fifteen positions, clustered toward the amino end, starve several proteases of a comfortable cut site and stiffen the chain against the acid unfold. That's why oral gavage studies in rats exist at all. They aren't a marketing claim about bioavailability in a person. They are a consequence of a proline-rich 15-mer that gastric juice itself selected. Mass 1419.5. Formula C62H98N16O22 for the free peptide; the lyophilised cake will also report trifluoroacetate or acetate depending on the cleavage and the salt exchange. Purity ≥98% HPLC is a peak, not a physiology. The origin story matters on a tendon page because the molecule didn't become a different chain when the model moved from indomethacin lesions to an Achilles insertion. It's still a gastric fragment wearing a second hat.

In short. BPC-157 is a fifteen-amino-acid piece of a stomach protein that survives acid because it's full of proline. That same chain is what the tendon papers used.

NSAID gastropathy is the original neighbourhood, and it belongs here so the tendon hat doesn't pretend to be the whole wardrobe. Indomethacin, diclofenac, aspirin: cyclo-oxygenase inhibition, prostaglandin collapse, a mucosa that can no longer keep its mucus and bicarbonate and blood flow, lesions a pathologist scores by area. André Robert’s cytoprotection was prostaglandin replacement without a change in acid secretion. Sikiric’s argument was that BPC-157 reduced lesion area in these models without being a prostaglandin, and that the protection reached intestinal and liver injuries NSAIDs also cause. Those papers are numerous. They are also, as a body, light on the randomisation and blinding a modern ulcer paper would insist on. The scientific value of the gastric work, for a tendon essay, is the chemical fact that a 15-mer survived the organ that invented it, plus a blood-flow chapter that made endothelium the next room. Blood flow is the sentence that leads to nitric oxide and to VEGFR2. The stomach was the door. The vessel was the room. The tendon was the corridor the vessel opened.

In short. The first BPC-157 papers were about stomach damage from anti-inflammatory drugs. Blood flow in that lining is how a stomach fragment walked into vessel and tendon work.

Once a stable peptide talks to endothelium, tendon-to-bone defects are an almost inevitable next model. A junction that has to be pulled apart and then take load is a vascular problem and a collagen problem. Rodent work on BPC-157 has reported faster tenocyte outgrowth, better collagen organisation, and a denser bed of small vessels. Chang’s 2011 Journal of Applied Physiology paper is the one a paper can actually pick up without buying the entire Zagreb philosophy: pentadecapeptide BPC-157 promoted tendon outgrowth, cell survival and cell migration in a rat Achilles neighbourhood, with FAK and paxillin implicated in the tenocyte. Starešinić and the Zagreb group ran transected Achilles and quadriceps defects, load-to-failure, collagen organisation, vascular density. A tendon heals slowly because it's poorly vascularised and because the collagen has to be laid in the line of force. Anything that persuades tenocytes to migrate, survive, and pull on a matrix, and that persuades a capillary to enter the defect, will move those endpoints in a rodent. Whether the 15-mer does that by VEGFR2, by FAK, by a nitric-oxide effect on the vessel, or by some combination, is the mechanistic question the better papers try to close with inhibitors.

In short. In rats, the 15-mer has been reported to help tendon cells crawl, survive and organise collagen, and to bring in small vessels. That's a rodent finding with named assays.

Outgrowth from an explant is closer to a mechanism than load-to-failure at six weeks, and both appear in the file. An explant is a piece of tendon on a dish, cells crawling off, a count, a kinase blot. It's cheap, inhibitor-friendly, and still a tenocyte if the tissue was tendon and the passage was early. Load-to-failure of a repaired Achilles is a different assay: biomechanical, weeks later, confounded by every systemic thing a peptide might have done to the animal, by the surgeon’s hands, by how the rat used the limb, by the hydration of the cable on the day you broke it. Both are allowed. Only the first is close to FAK. The second is a phenotype, and phenotypes are how in-vivo papers earn a figure, but they aren't VEGFR2. A lab that wants the 15-mer as a tenocyte probe should run the explant, the scratch, the phospho-FAK blot, and a collagen-gel contraction if they have the patience. A lab that wants a rodent biomechanics paper should budget for the six-week clock and for a surgeon who can make the defect the same way twice. Those are different grants. Neither is a human cuff protocol.

In short. Watching tendon cells crawl off a scrap of tissue is closer to a mechanism than breaking a repaired tendon six weeks later. Both appear in the papers. They answer different questions.

How a single-laboratory programme ages is a sociology of science before it's a verdict on a peptide. Effect sizes stay large. Journals stay specialised. Reviewers are often colleagues in the same injury field. Negative results, if they exist, are quieter. None of that is fraud; all of it is how academic careers work when a compound is yours. Predrag Sikiric, Seiwerth, and a rotating cast built, from about 1993, one of the largest preclinical peptide corpora in print, with a through-line they call organoprotection: a peptide that restores a physiological set-point after an insult, rather than one that simply stimulates a receptor. The nitric-oxide system is the set-point they named most often. Independent laboratories didn't reproduce the entire map, and nobody honest expected them to. What they did reproduce, in endothelium and in tendon fibroblasts, is enough to keep the 15-mer interesting as a probe. VEGFR2 phosphorylation and internalisation. Endothelial migration that a VEGFR2 inhibitor can blunt. Tenocyte outgrowth and a FAK–paxillin blot. That's a real, if still preclinical, object. It's also a much smaller object than the internet’s healing peptide.

In short. One lab publishing for decades will look bigger than it is. Other labs have repeated the blood-vessel and tendon-cell pieces more cleanly than the far-reaching claims.

VEGFR2 is KDR, Flk-1, a receptor tyrosine kinase. It isn't a GPCR. Seven-helix receptors, G proteins, arrestin, cyclic AMP — that's a different superfamily, and this catalogue uses it for incretins and ghrelin mimetics and melanocortins. VEGFR2 is a single-pass transmembrane protein with an extracellular immunoglobulin-like ligand domain and an intracellular kinase. VEGF-A dimers it; the kinase domains autophosphorylate; PLCγ, PI3K–Akt, Src, and a FAK neighbourhood are among the effectors; endothelial survival, migration and proliferation follow. Internalisation of VEGFR2 isn't merely turning the receptor off. Endocytic traffic of VEGFR2 is part of how the angiogenic signal is shaped, and Hsieh’s BPC-157 paper sits on that traffic: the pentadecapeptide associated with VEGFR2 activation and internalisation, with Akt and eNOS downstream. You can disagree with a figure. You can't relabel an RTK as a GPCR because the rest of the catalogue is GPCRs, and you can't relabel it as an actin-binding motif because a forum stacked two vials. The lock is an RTK. The downstream cascade still amplifies. The lock is still not LKKTETQ.

In short. The blood-vessel receptor named in the cleaner BPC-157 papers is a membrane enzyme, not a seven-helix hormone lock, and not an actin-binding sequence.

Focal-adhesion kinase is how a tendon paper and an endothelium paper can share a kinase without sharing a tissue. FAK sits at integrin clusters where a cell grips extracellular matrix. Autophosphorylation at Tyr397 recruits Src; paxillin and p130Cas are phosphorylated; Rac and the actin machinery are told that the grip is real and that a protrusion may proceed. Chang’s tenocyte work put FAK and paxillin on the BPC-157 page. Endothelial migration uses the same adhesion kinase because crawling is crawling. A peptide that lights FAK in two cell types isn't therefore a universal repair juice. It's a peptide that may feed a kinase two cell types already use to move. The blot is phospho-FAK, phospho-paxillin, a FAK inhibitor (PF-573228 is the one people reach for), and a scratch that should stall when the kinase is blocked. If the scratch doesn't stall, FAK was a spectator, and you have learned something the paper you're citing did not. Tenocytes aren't endothelial cells. They live in a dense collagen hierarchy, see load as their growth factor, and migrate poorly compared with a human umbilical-vein endothelial cell. Shared kinase, different cell, different tissue clock.

In short. A cell uses this kinase to know it's gripping the surface it wants to crawl on. Tendon cells and vessel cells both use it. Sharing a kinase isn't sharing a tissue.

eNOS is endothelial nitric-oxide synthase, phosphorylated at Ser1177 by Akt among other kinases, and that phosphorylation is a standard Western readout of an angiogenic or shear-stress programme. Nitric oxide then is the gas: short-lived, locally acting, a relaxant of smooth muscle, a modulator of platelet and leukocyte stickiness, a player in VEGF's own vascular-permeability effects. Sikiric's reset language — L-NAME makes lesions worse, L-arginine can make them better, BPC-157 nudges the animal back toward the middle from either side — and Hsieh's eNOS phosphorylation can live in the same neighbourhood without being the same claim. One is a two-sided physiological set-point across organ systems. The other is a kinase on a blot in a cultured endothelial cell. A new experiment should pick which sentence it is testing. Organ-bath aortic rings, L-NAME, haemoglobin as an NO scavenger, and an eNOS phospho-antibody will do for the vessel. A tendon-to-bone load-to-failure plus a vascular-density count will do for the insertion. Doing both and calling them one mechanism is how a neighbourhood becomes a catchphrase. On a hypovascular cable, the catchphrase is tempting. The blot is still the adult sentence.

In short. A blood-vessel enzyme makes nitric oxide, a short-lived gas that opens vessels. The original group talks about resetting that tone. Outside labs more often show a phosphorylation on a blot.

Hypovascular tissue notices vessels, which is the only good reason a gastric angiogenic probe keeps being filed under tendon. A defect that can't recruit capillaries won't feed the tenocytes that are trying to write collagen I in the line of force. A mid-portion that has already grown the wrong vessels and the wrong nerves won't automatically thank you for more of either. Direction, dose, clock, and which tendon you meant are the variables a paper has to name. Bevacizumab and ramucirumab occupy VEGFR2 in the opposite direction, in oncology, as licensed antibodies; that neighbourhood is a reminder that angiogenesis is politics, not a vitamin. A research 15-mer in a rodent insertion model isn't those antibodies. It's also not a reason to write 'boosts blood flow' on a tendon caption and sit down. The independent endothelial work — migration, VEGFR2 internalisation, Akt, eNOS — is the node a new bench should occupy first. The tendon phenotype is allowed to follow if the node holds. The node doesn't follow from a forum that already wanted the phenotype.

In short. A tendon defect needs small vessels to feed the cells writing collagen. Degenerate tendon can already have the wrong vessels. Angiogenesis is a measurement, not automatically a victory.

TB-500 is a trade name that has been used, carelessly, for more than one chain. Full-length thymosin β4 is forty-three amino acids, acetylated at the N-terminus in the native protein, mass about 4.96 kilodaltons, the principal G-actin sequestering peptide in most mammalian cells. Research material sold as TB-500 has often been an analogue built around the LKKTETQ actin-binding motif, sometimes the motif itself, sometimes a longer fragment, sometimes, if the certificate is honest, the 43-mer. The only adult response to that mess is to read the certificate. Sequence, mass, HPLC purity, the counter-ion. If those lines are missing, you don't have a ligand, you have a rumour in a vial. A tendon bench that thinks it's replicating a Tβ4 cornea paper with a heptapeptide analogue hasn't replicated the paper. It has run a different molecule through a similar photograph. We stock an actin-binding analogue, sequence and mass on the certificate, so a scratch assay can name what it put in the well. We don't stock a synonym for BPC-157. Different sequence, different literature. Treating them as interchangeable is a category error this page won't make.

In short. TB-500 is a trade name, not a single chain. Full thymosin β4 is forty-three amino acids. Some vials are only the actin-binding piece. Read the mass or you don't know what you pipetted.

LKKTETQ is residues 17–23 of thymosin β4, the principal actin-binding motif identified by peptide-mapping and mutagenesis in the 1990s. Van Troys, Vandekerckhove, and the Hannappel and Safer laboratories did the biochemistry: the motif is necessary for G-actin sequestration; surrounding residues tune affinity; the N-terminal Ac-SDKP is a different pharmacophore entirely. A heptapeptide isn't a 43-mer. It doesn't carry the nuclear-localisation-ish story some Tβ4 papers tell, it doesn't carry the same extracellular signalling literature, and it doesn't generate Ac-SDKP when a prolyl oligopeptidase bites the N-terminus, because it has no such N-terminus. Treating motif, fragment, and full-length protein as one healing peptide is how three pharmacophores become a forum abbreviation. A blot can't tell them apart if you never ran the mass. A scratch assay can't tell them apart if you never ran a G-actin binding measurement. Name the chain. Then crawl. On a tendon page this matters twice: once because the analogue isn't BPC-157, and once because the analogue isn't automatically the molecule Sosne put on a cornea or Bock-Marquette put on a heart.

In short. Seven amino acids in the middle of thymosin β4 grab spare actin. That piece isn't the whole protein, and it isn't the separate anti-scarring fragment at the front end.

Allan Goldstein isolated the thymosins from thymus in the 1960s and 1970s as putative immune hormones. The immune-hormone frame was the frame of that decade. Thymosin β4’s ageing was more interesting. The protein is abundant in almost every cell, not just in thymocytes; it's one of the most plentiful peptides in a platelet; and the job that survived contact with biochemistry wasn't a hormone receptor. It was actin. Daniel Safer, in 1991, showed that thymosin β4 and Fx, an actin-sequestering peptide, were indistinguishable. A thymic hormone had been a cytoskeletal buffer all along. Huff, Müller, Otto, Netzker and Hannappel wrote the review a cytoskeleton lab actually cites: β-thymosins as small acidic peptides with multiple functions, International Journal of Biochemistry and Cell Biology, 2001. Intrinsically disordered. One-to-one with G-actin. A reservoir that profilin, cofilin and the barbed-end polymerases draw on when a lamellipodium is required. Expression high in platelets, macrophages, wound fluid. Release from dying or activated cells as an extracellular signal that, in later papers, moves VEGF, MMP-2 and keratinocyte migration. Inside the cell it's a monomer sponge. Outside, it's a peptide other cells can see. Those are two jobs.

In short. Thymosin β4 was first treated as an immune hormone. It turned out to be a common cell protein whose real job is holding spare actin, inside the cell and, after injury, outside it.

Actin treadmilling is the physics of a crawl. Monomers add to the barbed (plus) end of a filament and leave from the pointed (minus) end. In a lamellipodium the barbed ends face the membrane; polymerisation pushes; cofilin and tropomyosin and myosin help the rear keep up; adhesion complexes grip so the push becomes locomotion rather than blebbing. Pollard, Borisy, Theriot, and reconstituted motility papers made this a textbook cycle. Thymosin β4’s place in the cycle is the reservoir: a pool of G-actin that isn't free to add to barbed ends until a GEF, a profilin exchange, or a local drop in Tβ4 occupancy releases it. Profilin-actin is the form the barbed end actually wants. Cofilin severs and feeds the pool. Arp2/3 nucleates branches. Formins nucleate unbranched cables. The peptide doesn't replace any of those machines. It holds the spare parts. A cell that can't sequester G-actin has a noisy, poorly timed polymerisation. A cell that can't release G-actin can't push. Injury, and extracellular cues, change how much of the buffer is available, and where. That's why an actin analogue shows up in a scratch. It isn't why it shows up in a VEGFR2 sentence.

In short. Cells crawl by adding actin building blocks at the front of a filament and taking them off at the back. Thymosin β4 holds the spare blocks until the front needs them.

A scratch assay scores, crudely, whether lamellipodia closed a gap. Fibroblasts close scratches because you fed them, because the density was wrong, because the pipette tip released a wound signal, because a peptide did something interesting. Tenocytes close them more slowly. Endothelial cells close them faster, and VEGF in the serum is already a ligand. Tβ4 shifts the G/F-actin ratio toward G if it sequesters; a motif analogue should do the same if it sequesters, and should fail if the well contains a chain that never bound actin. That's the blot-level distinction we'll keep promising: not an antibody against a brand name, a biochemical activity. DNase I inhibition, pyrene-actin polymerisation, a pull-down with biotin-actin. Those assays were old when the internet named TB-500. They still work. Running a scratch without them is how you generate a phenotype you can't attribute. Running them without HPLC-MS is how you attribute a phenotype to the wrong chain. The order is identity, activity, then the prettier picture of cells crawling into a gap. A closed gap isn't a tendon. A closed gap isn't a crush. A closed gap is a gap that closed.

In short. The usual dish test is a scratch in a sheet of cells. Gaps close for many reasons. Measure whether the peptide actually grabbed actin before you caption the photograph.

Ac-SDKP is N-acetyl-seryl-aspartyl-lysyl-proline, the N-terminal tetrapeptide of Tβ4, generated physiologically by prolyl oligopeptidase. It's an anti-fibrotic and angiogenesis-modulating peptide with an ACE-adjacent literature: angiotensin-converting enzyme degrades Ac-SDKP, ACE inhibitors raise it, and some of the anti-fibrotic benefit of ACE inhibitors has been argued to run through this tetrapeptide. Carretero’s group spent years on that axis. Ac-SDKP isn't an actin sequesterer. It doesn't carry LKKTETQ. Lumping it with motif-only TB-500 and with 43-aa Tβ4 under one healing-peptide label is how a literature gets garbled into a stack, and a stack is already how this page’s two protagonists got garbled. Three pharmacophores, three assays. G-actin binding for the motif. Hydroxyproline and collagen I architecture for the tetrapeptide’s anti-fibrotic claim. The full 43-mer when your model is Sosne’s cornea or Srivastava’s heart. A certificate that can't tell you which of those three you reconstituted has already failed, before any tenocyte was seeded. Keep the three names on three tubes, and keep all three off the BPC-157 tube.

In short. A four-amino-acid piece snipped from the front of thymosin β4 has its own anti-scarring papers. It doesn't bind actin. Treat it as a third molecule, not a nickname.

Full-length Tβ4 has been nearer to a person than either research analogue on this page, which is a historical fact and not a caption for the motif cake. Sosne’s alkali-injury cornea work, and the RegeneRx RGN-259 ophthalmic and RGN-137 dermal programmes, used characterised 43-mer in formulated products. Mixed human readouts, not empty ones. Bock-Marquette, Saxena, White, Dimaio and Srivastava, Nature 2004, used the 43-mer in a coronary-ligation model and named integrin-linked kinase, which is another focal-adhesion neighbourhood protein and still not VEGFR2. Those programmes and papers are the clinical-adjacent neighbour of the research analogue, and they aren't the analogue, and they aren't BPC-157. Citing a Phase 2 ophthalmic study as evidence for a motif peptide in a tendon scratch is a category error. Citing it as evidence that actin-buffer biology can reach a person is a fair historical sentence. BPC-157’s published literature remains a large preclinical corpus. Preclinical is a class of evidence. It isn't a missing Phase 3 that someone forgot to publish, and it isn't a reason to write the 15-mer as if it had sat in the same trial as RGN-259.

In short. Some human eye and skin studies used the full thymosin-β4 protein as a formulated product. That's a neighbour of the research analogue, not a stand-in for it, and not a BPC-157 trial.

The internet bundled BPC-157 and TB-500 because both had large, positive, preclinical injury literatures, both were short enough to synthesise on a solid-phase rig, both were unlicensed, and both photographed well as a stack. Tendon threads wanted a vessel peptide and a crawl peptide and didn't want to learn two mechanisms. A pair of lyophilised cakes with similar reconstitution instructions is a commercial object. It isn't a biochemical object. There's no heterodimer. There's no shared receptor. There's no paper in which a defined molar ratio of GEPPPGKPADDAGLV and LKKTETQ was the independent variable and a named kinase the dependent one. Phenotype rhyme — both look like repair in a rodent — is the weakest reason to co-administer two ligands, and the most common. We have watched that rhyme travel for years. One talks to VEGFR2 and FAK. The other parks actin. Forums say healing stack. Biochemistry says vessel-and-NO ligand plus actin buffer. Different blots. If a blot can't tell them apart, they shouldn't be in the same well until the blot can.

In short. People paired them because both showed up in injury stories and both were easy to vial. Shared rumour isn't a shared receptor. No paper makes them one drug.

There's a softer reason the pairing stuck, and it isn't foolish. A wound bed needs a vessel and a crawling cell. Angiogenesis without migration is a leaky granulation tissue. Migration without a blood supply is a sheet that dies in the middle. A tendon defect is a wound bed with unusually high standards for the matrix it'll accept: aligned collagen I, not a scar, a blood supply that came and then quietened, a nerve that didn't sprout into the fascicles. Combining an angiogenic probe with a cytoskeletal probe is, as a hypothesis, the sort of thing a tumour biologist already knows from VEGF plus integrin papers. The hypothesis is lawful. The leap from hypothesis to a fixed pair of research peptides, at folkloric ratios, in the absence of a factorial experiment, is not. The factorial is: BPC-157 alone, TB-500 alone, both, neither, on a named readout, with identity confirmed. Until that figure exists in a paper you trust, the stack is a rhyme. A bench that ran the factorial once would teach the field more than a hundred threads repeating the rhyme. The vials will still be here in the morning. The factorial is the work.

In short. A healing wound does need both new vessels and crawling cells, so pairing the ideas is a fair hypothesis. It's still a hypothesis until someone tests each peptide alone and both together.

Other repair-adjacent peptides live on the same shelf and get swept into the same sentence, which is how a two-ligand confusion becomes a four-ligand caption. GHK-Cu is a copper-binding tripeptide with a fibroblast transcriptome; Pickart’s arrays are the documents, and they aren't VEGFR2. KPV is a melanocortin tripeptide with a PepT1 uptake story and an NF-κB quieting in barrier epithelium; that's a gut-lining essay on this desk, not a tendon one. GLOW, where it's listed, is those ideas lyophilised together with BPC-157 and TB-500 so a bench that wants four named sequences doesn't open four caps. That's a logistics decision. It isn't a claim that copper delivery, actin sequestration, VEGFR2 traffic and a PepT1 cargo share a pathway, and it isn't a protocol for a rotator cuff. A blend is a convenience. A stack, in forum language, is a protocol. This catalogue will sell the convenience to a laboratory that can name the chains. It won't launder it into a protocol. Related in folklore. Unrelated in mechanism. Two certificates for the two sequences this page is about, and a refusal to flatten them into one caption.

In short. A copper tripeptide and a barrier tripeptide sit in nearby repair conversations. Putting several chains in one vial is a packing choice. It doesn't make them one pathway.

Mass first. BPC-157 at 1419.5 daltons can't be mistaken for a 5-kDa Tβ4 analogue on a mass spectrometer, and a motif heptapeptide is smaller still. If the certificate already has the mass, repeat it on the reconstituted stock, because lyophilised peptides are hygroscopic, labels smudge, and the tube you think is the 15-mer is, in a crowded freezer, sometimes the other tube. HPLC second, not as a purity performance but as a peak you can collect and put back on the mass spectrometer if the assay misbehaves. Antibody third, and only if you trust the antibody. Anti-Tβ4 antibodies exist; they won't see BPC-157. Anti-BPC-157 antibodies are rarer and should be treated as guilty until a spike-in and a preabsorption control say otherwise. Phospho-VEGFR2, phospho-FAK, phospho-eNOS, and a G/F-actin ratio are the activity blots. They don't identify the peptide. They identify a cellular response. A response without an identity is a story about the well, not about the ligand. On a tendon explant that matters, because tenocytes will crawl a little for many reasons, and a crush homogenate will phosphorylate many things for many more.

In short. Weigh the chain on a mass spectrometer first. The stomach peptide and the actin peptide can't hide as each other. Activity blots then tell you what the cells did, not what you added.

Orthogonal readouts are how you stop lying to yourself. For the 15-mer: a VEGFR2 phosphorylation that a VEGFR2 inhibitor abolishes; an endothelial scratch that SU5416 reopens; an eNOS Ser1177 blot; perhaps an aortic-ring relaxation that L-NAME blunts; a tenocyte explant whose outgrowth a FAK inhibitor stalls. For the actin analogue: a pyrene-actin polymerisation curve that shifts as a sequesterer should; a G/F ratio; a scratch that a cytoskeletal poison (latrunculin, at a dose you have titrated) interprets; a motif mutant or a scrambled peptide as the negative ligand. If both peptides close a scratch, and only one of those orthogonal sets moves, you have learned that a scratch is a low-specificity endpoint. Which it is. Running both peptides in the same tendon explant without the panel is the folkloric experiment, and it'll give you the folkloric result: both worked. Of course they did. Cells leave explants. The blot panel is how you find out which job you paid for. Muscle-crush endpoints are dirtier still: function scores, fibre cross-section, a scar fraction. Dirty endpoints need cleaner ligands, not the other way around.

In short. Use vessel-signal tests for one peptide and actin-binding tests for the other. If both close a gap but only one set moves, the gap test was too easy.

A Western is a denatured protein on a membrane, an antibody, a peroxidase, a film or a digital imager. It isn't magic, and it isn't identity. Phospho-antibodies report a pool, not a pathway, until the inhibitor arm is there. Loading controls report that you put similar protein in each lane, not that the biology was similar. For actin, a Western for Tβ4 can confirm the peptide entered a lysate; it can't confirm sequestration. For BPC-157, there is often nothing to Western but the downstream kinases, because a 15-mer may not have an antibody you trust. Mass spectrometry of the medium, before and after the incubation, will tell you whether the 15-mer survived the well. Peptides disappear. Proteases in serum, adsorption to plastic, a pH you didn't measure. A disappearing ligand is a classic way to generate a negative result that the molecule didn't earn, or a positive one that belongs to a fragment you never named. Serum is a VEGF bath and a protease bath. Write the percentage. Write the time. Write the quench. The cake in the vial is only as informative as the minute you chose to stop the chemistry.

In short. A blot shows a protein the antibody can see, not the peptide you think you added. Measure the peptide in the dish at the end. Short chains vanish into plastic and enzymes.

Identity, then activity, then phenotype. That order is the whole paper. HPLC-MS of the cake. HPLC-MS of the reconstituted stock. A concentration you actually measured, not a nominal microgram-per-millilitre from a label that assumed the cake was dry and the balance was true. Vehicle matched: acetic acid, TFA residual, bacteriostatic water, whatever you used, in the control wells at the same volume. Serum stated. A cell type that has the machinery you claim — human umbilical-vein endothelial cells for VEGFR2, primary tenocytes or a decent tendon line at a declared passage for FAK, a myoblast or satellite-cell preparation if you're in the crush neighbourhood, a keratinocyte or corneal epithelial line if you've wandered into Sosne by mistake. Species stated, because a rat VEGFR2 isn't a human VEGFR2 and a forum dose in milligrams isn't a nanomolar occupancy in a well. Then the inhibitor. Then the n. Then the thing you actually wanted to photograph. Reverse that order and you'll photograph something. You won't know what it was. A tendon photograph is particularly seductive. Alignment looks like virtue. Alignment without identity is a pretty scar.

In short. First prove what is in the tube, then prove it does the chemistry you claim, then take the pretty picture. Reverse that order and you only have a picture.

Dose is where folklore does its worst work. In-vitro endothelial papers that named VEGFR2 used nanomolar-to-micromolar BPC-157, which is a lawful range for a peptide against a receptor if the Kd lives there, and we do not, in public, have a clean Kd. In-vivo rodent papers used micrograms to milligrams per kilogram, by gastric gavage or by injection, on clocks from hours to weeks. Tβ4 cardiac and corneal papers used their own microgram-range local doses. A forum that collapses those into a single human milligram figure has performed a unit conversion that physics didn't authorise. A research well should start at a log series around the concentrations the paper you're replicating actually used, and should include a zero and a toxic high. If the phenotype only appears at a concentration that detaches the monolayer, you have a detergent, not a ligand. If it appears at one point on the curve and vanishes on either side, you may have a real pharmacology, and you should be happy, because biphasic curves are how a lot of honest peptide biology looks. Write the curve. Do not pick the point that flattered the hypothesis.

In short. Papers use very different amounts in a dish and in an animal. Copy the range from the paper you're repeating, include a zero, and don't keep only the dose that looked nicest.

Species, sex, age and passage aren't footnotes. A young male Sprague-Dawley rat with a transected Achilles is the animal a lot of the tendon papers used. An ovariectomised female, an aged animal, a diabetic animal, a different species, will move the same endpoints differently, and the Sikiric corpus sometimes did those variants and sometimes did not. Human tendinopathy is mostly a middle-aged, mixed-sex, loaded-for-years object with a continuum of degenerate matrix, not a clean transection in an eight-week-old rodent. Endothelial cells from human umbilical vein are a foetal, venous, proliferative population that isn't a tendon capillary and not an adult artery. They are still the workhorse if you say so. Primary tenocytes lose scleraxis and start looking like generic fibroblasts; passage number belongs in the methods. C2C12 myoblasts aren't satellite cells in a crush. None of this is a reason to stop. It's a reason to stop writing as if a HUVEC scratch were a person, and as if a rat insertion were a painful mid-portion Achilles. Preclinical is a class of evidence. It isn't a small human trial that someone forgot to publish.

In short. Rat tendons, umbilical-vein cells and a middle-aged human tendon are different systems. Say which one you used. A dish result is real and still not a human study.

Controls are the part a methods reviewer can still save. Scrambled peptide, same mass, different sequence. Heat-inactivated peptide, if the activity should be sequence-specific and not a contaminant. Vehicle. Inhibitor. A positive control that must work or the week is void: VEGF for an endothelial scratch, serum for a fibroblast, a known sequesterer for a pyrene-actin curve, an eccentric-loading group if you're ambitious enough to put a peptide against the clinic’s actual tool. Blinded scoring of lesion area, of collagen organisation, and of biomechanical testing, because those endpoints are where hope enters the callipers. At minimum, a written analysis plan before the first blot, so that the phospho-antibody you added on Friday isn't the one that worked. The analogue and the 15-mer will survive contact with a proper control. If they do not, they weren't what the caption said, and that's a result worth publishing. A factorial — each peptide, both, neither — is the experiment the stack has owed the field for years. Run it on one named readout. Publish the empty cells as well as the full ones.

In short. Include a scrambled chain, the liquid without peptide, a drug that should block the effect, and a treatment you already know works. If those are missing, the figure is a draft.

Repair, for BPC-157, is a cytoprotective and angiogenic idea that escaped a stomach. A proline-rich 15-mer survived acid, talked to mucosa, and then, on the papers a biochemist can run, talked to VEGFR2 and to FAK in endothelium and tenocytes, with an eNOS-dependent nitric-oxide tone that the Zagreb group would like you to read as a reset. Tendon-to-bone and muscle crush are the models that made a gym culture notice a gastric fragment. The chemistry didn't change when the tissue did. GEPPPGKPADDAGLV is still the chain. Repair, for TB-500, is a cytoskeletal idea that escaped a thymus. A disordered 43-mer turned out to be the cell’s G-actin sponge; injury spilled it; lamellipodia spent it; an analogue around LKKTETQ put that sponge on a certificate. Those are two ideas. They rhyme at the level of a wound bed, which needs a vessel and a crawling cell. They don't rhyme at the level of a receptor, a kinase, a monomer, or a mass spectrum. A tendon is a hypovascular collagen I cable. A crushed muscle is a myofibre necrosis with a satellite-cell clock. Folklore stacked the tissues and then stacked the ligands. Anatomy and biochemistry both refuse the stack.

In short. One peptide is a stomach fragment that talks to vessel and tendon cells. The other holds actin. A wound might need both jobs. They are still two molecules and two injuries.

The neighbouring essays on this desk take the molecules apart and leave this page to take the tissues apart. BPC-157 and TB-500: two different ideas of repair — the joint distinction at catalogue length, folklore against blot. BPC-157: the pentadecapeptide that survived the stomach — gastric cytoprotection, the Zagreb corpus, the VEGFR2 node, NSAID lesions as the original sandbox. TB-500 and thymosin β4: repair is a cytoskeletal programme — Goldstein, Safer, Huff, Sosne, Bock-Marquette, Ac-SDKP as a third pharmacophore. Read them in any order. Do not read them as a protocol. The living-cell essays — how peptides talk to cells, actin as a city-scale object, pathophysiology from genome to a tendon that won't settle — are the physics underneath both vials. A research peptide is a few nanometres of chain. The cell it meets is a packed interior with ten billion proteins. The tendon it's asked to serve is a fibre-composite that replaces its core collagen on a timescale of decades. Scale was always the point. The stack was always a way of not looking at scale.

In short. Separate essays cover each peptide on its own. This one exists to keep tendon, crush and the two ligands from collapsing into a pair. Read the cell-scale pieces if you want the physics underneath.

What we won't do is dose. We won't tell you how to combine the vials, how many milligrams, how many weeks, or what a person should expect from a rodent tendon. Those sentences are protocols, and protocols for unlicensed peptides are how a journal becomes a problem. The papers that already ran the models wrote their methods: gavage or injection, species, clock, endpoint. Go there if you're running an experiment. Stay here if you wanted the two tissues distinguished from each other and the two ligands distinguished from the tissues. Soft-tissue medicine remains loading, imaging, and surgery when the cable is gone. Muscle crush in a person remains a compartment-pressure question before it is anything else. The 15-mer on the shelf is GEPPPGKPADDAGLV. The analogue on the shelf orbits LKKTETQ. Both listings are lyophilised research peptides, HPLC-characterised, labelled for laboratory use only. They are neither medicines nor a stack. They are two probes, and the blot is how you tell which probe you're holding.

In short. This isn't a dosing guide and not a medicine. Both vials are lab reagents with certificates. The interesting part was always which job each chain can do, in which tissue.

Research-use-only. Not for human consumption / not a medicine. The lyophilised BPC-157 and TB-500 on these listings are laboratory reagents, HPLC-characterised, labelled for in-vitro work: an explant, a scratch, a pyrene-actin curve, a VEGFR2 blot, a crush homogenate whose satellite cells you actually count. The physiology in the paragraphs above is public, cited, and older than either vial. Use it to design the experiment you have the controls for, with the tissue named, the insult named, the ligand named, and the time point written down. Read Chang, read Hsieh, read Safer, read Huff, then weigh the cake you actually opened. We'll sell you the named sequences. We won't tell you they are one healing peptide, and we won't tell you a hypovascular cable and a crushed myofibre are one injury. A tendon is collagen I in a hierarchy. A crush is a stem-cell race against scar. The peptides are two different jobs. Measure them as two.

In short. The vials are research chemicals for experiments, not medicines and not food. The biology is public. Name the tissue, name the chain, and keep the claim the size of the chromatogram.